Cited by 867Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Bolinder, Jan, Ljunggren, Östen, Kullberg, Joel, Johansson, Lars, Wilding, John, Langkilde, Anna Maria, Sugg, Jennifer, Parikh, Shamik·2012·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2011-2260

Open this paper in CoChat — free account

Abstract

CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1210/jc.2011-2260

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Metabolic Syndrome Pandemic
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21

Sorted by citations

Items 201–300 of 864

Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials
Coelho, F. D. S., Borges‐Canha, M., von Hafe, M., Neves, J. S., Vale, C., Leite, A. R., Carvalho, D., & Leite‐Moreira, A. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3413 · Cited by 61
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options
Chiu, C., Du, Y., Ou, H., & Beverly, E. A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s53482 · Cited by 67
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
Singh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 63
Metabolically healthy obesity: Misleading phrase or healthy phenotype?
Tanrıöver, C., Çöpür, S., Gaipov, A., Özlüşen, B., Akcan, R. E., Kuwabara, M., Hornum, M., van Raalte, D. H., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.025 · Cited by 68
Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study
Kashiwagi, A., Akiyama, N., Shiga, T., Kazuta, K., Utsuno, A., Yoshida, S., & Ueyama, E. (2014) · Diabetology International · doi:10.1007/s13340-014-0184-9 · Cited by 60
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ferrannini, E., Murthy, A. C., Lee, Y., Muscelli, E., Weiss, S. J., Ostroff, R. M., Sattar, N. A., Williams, S. A., & Ganz, P. (2020) · Diabetes Care · doi:10.2337/dc20-0456 · Cited by 61
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
Kaku, K., Maegawa, H., Tanizawa, Y., Kiyosue, A., Ide, Y., Tokudome, T., Hoshino, Y., JISIN, Y., & Langkilde, A. M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0086-7 · Cited by 61
Self-citation
Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis
Elkazzaz, S. K., Khodeer, D. M., Fayoumi, H. M. E., & Moustafa, Y. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119018 · Cited by 60
Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
Kanbay, M., Tapoi, L. C., Ureche, C., Tanrıöver, C., Çevik, E., Demiray, A., Afşar, B., Cherney, D. Z. I., & Covic, A. C. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02943-2 · Cited by 67
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
Whaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 60
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy
Yamamoto, K., Miyoshi, H., Ono, K., Sugawara, H., Kameda, R., Ichiyama, M., Yamamoto, K., Nomoto, H., Nakamura, A., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0749 · Cited by 60
SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 65
Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention
Otten, J., Mellberg, C., Ryberg, M., Sandberg, S., Kullberg, J., Lindahl, B., Larsson, C. L., Hauksson, J. B., & Olsson, T. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.4 · Cited by 60
Self-citation
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
Takeshige, Y., Fujisawa, Y., Rahman, A., Kittikulsuth, W., Nakano, D., Mori, H., Masaki, T., Ohmori, K., Kohno, M., Ogata, E., et al. (2016) · Hypertension Research · doi:10.1038/hr.2016.2 · Cited by 59
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
Okamoto, A., Yokokawa, H., Sanada, H., & Naito, T. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0137-9 · Cited by 59
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Budd, J. T., & Cusi, K. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01349-1 · Cited by 62
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 64
SGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 62
Cardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 58
Dapagliflozin as add‐on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12634 · Cited by 60
Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes
Mikhail, N. E. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.854 · Cited by 57
Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat
Iacobellis, G., & Baroni, M. G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 61
Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials
Sakai, S., Kaku, K., Seino, Y., Inagaki, N., Haneda, M., Sasaki, T., Fukatsu, A., Kakiuchi, H., & Samukawa, Y. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.017 · Cited by 57
Dapagliflozin‐induced weight loss affects 24‐week glycated haemoglobin and blood pressure levels
Sjöström, C. D., Hashemi, M., Sugg, J. E., Ptaszynska, A., & JOHNSSON, E. K. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12500 · Cited by 56
Self-citation
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 57
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
Sugizaki, T., Zhu, S., Guo, G., Matsumoto, A., Zhao, J., Endo, M., Horiguchi, H., Morinaga, J., Tian, Z., Kadomatsu, T., et al. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0012-0 · Cited by 59
SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice
Soares, R. N., Ramirez‐Perez, F. I., Cabral-Amador, F. J., Morales‐Quinones, M., Foote, C. A., Ghiarone, T., Sharma, N., Power, G. J., Smith, J. A. H., Rector, R. S., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00563-x · Cited by 58
Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)
Kashiwagi, A., Shiga, T., Akiyama, N., Kazuta, K., Utsuno, A., Yoshida, S., & Ueyama, E. (2014) · Diabetology International · doi:10.1007/s13340-014-0182-y · Cited by 55
The renal effects of SGLT2 inhibitors and a mini-review of the literature
Andrianesis, V., Glykofridi, S., & Doupis, J. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816676239 · Cited by 56
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
Scheen, A. J. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.01.002 · Cited by 60
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
Narendran, P., & Saeed, M. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50963 · Cited by 58
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., & Shibata, H. (2022) · Medicines · doi:10.3390/medicines9090047 · Cited by 53
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies
Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.134 · Cited by 53
Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes
Uchiyama, S., Sada, Y., Mihara, S., Sasaki, Y., Sone, M., & Tanaka, Y. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4987 · Cited by 53
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 59
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
Mudaliar, S. R. D., Armstrong, D. A., Mavian, A. A., O'Connor‐Semmes, R. L., Mydlow, P. K., Ye, J., Hussey, E. K., Nunez, D. J., Henry, R. R., & Dobbins, R. L. (2012) · Diabetes Care · doi:10.2337/dc12-0508 · Cited by 53
Pharmacological Approaches in the Treatment and Maintenance of Weight Loss
Gaal, L. V., & Dirinck, E. L. (2016) · Diabetes Care · doi:10.2337/dcs15-3016 · Cited by 55
Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes
Sawada, K., Karashima, S., Kometani, M., Oka, R., Takeda, Y., Sawamura, T., Fujimoto, A., Demura, M., Wakayama, A., Usukura, M., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej17-0440 · Cited by 53
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Margonato, D., Galati, G., Mazzetti, S., Cannistraci, R., Perseghin, G., Margonato, A., & Mortara, A. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10024-2 · Cited by 54
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
Dwinata, M., Putera, D., Hasan, I., & Raharjo, M. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102173 · Cited by 51
Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
Huang, C.-C., Chou, C., Chen, W., Yang, J., Lee, W., Chen, J., Lee, C., & Li, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212408 · Cited by 56
Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
Seino, Y., Yabe, D., Sasaki, T., Fukatsu, A., Imazeki, H., Ochiai, H., & Sakai, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12694 · Cited by 50
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Choi, D., Jung, C., Mok, J., Kim, C., Kang, S.-K., & Kim, B. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.3.387 · Cited by 50
A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
Cusi, K. J. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 53
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Täger, T., Atar, D., Agewall, S., Katus, H. A., Grundtvig, M., Cleland, J. G. F., Clark, A. L., Fröhlich, H., & Frankenstein, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09954-8 · Cited by 53
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Škrabić, R., Kumrić, M., Vrdoljak, J., Rušić, D., Skrabic, I., Vilović, M., Martinović, D., Duplancic, V., Kurir, T. T., & Božić, J. (2022) · Biomedicines · doi:10.3390/biomedicines10102458 · Cited by 51
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment period
Araki, E., Onishi, Y., Asano, M., Kim, H., Ekholm, E., JOHNSSON, E. K., & Yajima, T. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12453 · Cited by 50
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
Fioretto, P., Mansfield, T. A., Ptaszynska, A., Yavin, Y., JOHNSSON, E. K., & Parikh, S. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0382-1 · Cited by 51
Self-citation
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F. N., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 52
The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
Kawalec, P., Mikrut, A., & Łopuch, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2494 · Cited by 49
Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 51
SGLT2 inhibitors
Dardi, I., Kouvatsos, T., & Jabbour, S. A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.09.005 · Cited by 52
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
Basile, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.004 · Cited by 47
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
Rahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 47
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
den Kamp, Y. J. M. O., Gemmink, A., de Ligt, M., Dautzenberg, B., Moonen‐Kornips, E., Jörgensen, J. A., Schaart, G., ESTERLINE, R. L., Pava, D., Joris Hoeks, J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101620 · Cited by 46
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 56
The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4806-9 · Cited by 46
Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus
Koike, Y., Shirabe, S., Maeda, H., Yoshimoto, A., Arai, K., Kumakura, A., Hirao, K., & Terauchi, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.029 · Cited by 47
Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis
El Masri, D., Ghosh, S., & Jaber, L. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.004 · Cited by 45
Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options
Cornell, S. A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s67387 · Cited by 70
Dapagliflozin in patients with type 2 diabetes mellitus
Filippatos, T. D., Liberopoulos, E. N., & Elisaf, M. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558243 · Cited by 44
Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea
Lozano‐Ortega, G., Goring, S. M., Bennett, H. A., Bergenheim, K., Sternhufvud, C., & Mukherjee, J. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1135110 · Cited by 44
Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 46
Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 49
Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
Grandy, S., Hashemi, M., Langkilde, A., Parikh, S. J., & Sjöström, C. D. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12263 · Cited by 44
Self-citation
SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus
Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 44
SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 46
Sodium–glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus
Raskin, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2403 · Cited by 42
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
Li, Y., Li, H., Li, H., Bui, A., Chang, M., Liu, X., Kasichayanula, S., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.017 · Cited by 43
Long‐term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
Leiter, L. A., Cefalu, W. T., de Bruin, T. W., Xu, J. L., Parikh, S. J., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12666 · Cited by 44
Self-citation
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus
Elkind-Hirsch, K. E., Seidemann, E. L., & Harris, R. (2020) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2020.100139 · Cited by 43
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Impact of Sodium‐Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
Trujillo, J. M., & Nuffer, W. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1903 · Cited by 42
Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
Hazem, R. M., Ibrahim, A. Z., Ali, D. A., & Moustafa, Y. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108503 · Cited by 42
SGLT-2 Inhibitor Therapy Added to GLP-1 Agonist Therapy in the Management of T2DM
Saroka, R. M., Kane, M. P., Busch, R. S., Watsky, J., & Hamilton, R. A. (2015) · Endocrine Practice · doi:10.4158/ep15877.or · Cited by 43
Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes
Tosaki, T., Kamiya, H., Himeno, T., Kato, Y., Kondo, M., Toyota, K., Nishida, T., Shiroma, M., Tsubonaka, K., Asai, H., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7196 · Cited by 42
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 45
Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
Ishii, S., Nagai, Y., Sada, Y., Fukuda, H., Nakamura, Y., Matsuba, R., Nakagawa, T., Kato, H., & Tanaka, Y. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3647 · Cited by 44
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies
Phillip, M., Mathieu, C., Lind, M., Araki, E., Bartolo, P. D., Bergenstal, R. M., Heller, S. R., Hansen, L., Scheerer, M. F., THOREN, F. A., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14248 · Cited by 42
Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Lauritsen, K. M., Voigt, J. H., Pedersen, S. B., Hansen, T. K., Møller, N., Jessen, N., Gormsen, L. C., & Søndergaard, E. (2022) · Endocrine Connections · doi:10.1530/ec-21-0558 · Cited by 43
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses
Zhang, Q., Dou, J., & Lu, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.006 · Cited by 41
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
Charokopou, M., McEwan, P. C., Lister, S., Callan, L., Bergenheim, K., Tolley, K. H., Postema, R. J., Townsend, R., & Roudaut, M. (2015) · BMC Health Services Research · doi:10.1186/s12913-015-1139-y · Cited by 41
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus
Shao, H., Zhai, S., Zou, D., Mir, M. U., Zawadzki, N. K., Shi, Q., Liu, S., & Shi, L. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1257978 · Cited by 42
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 42
Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
Matsumura, M., Nakatani, Y., Tanka, S., Aoki, C., Sagara, M., Yanagi, K., Suzuki, K., & Aso, Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0274-3 · Cited by 41
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
Poudel, R. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113725 · Cited by 44
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40
Efficacy and safety of empagliflozin for type 2 diabetes mellitus
Zhang, Y., Han, S., Sun, X., Wang, S., Wang, H., Liu, X., Chen, L., & Xia, L. (2018) · Medicine · doi:10.1097/md.0000000000012843 · Cited by 40
GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 41
Peripheral targets in obesity treatment: a comprehensive update
Chatzigeorgiou, A., Kandaraki, E., Papavassiliou, A. G., & Koutsilieris, M. (2014) · Obesity Reviews · doi:10.1111/obr.12163 · Cited by 44
Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes
Peene, B., & Benhalima, K. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814553965 · Cited by 41
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Weight in Patients With Type 2 Diabetes Mellitus
Barnett, A. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2698 · Cited by 43
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
Iizuka, T., Iemitsu, K., Takihata, M., Takai, M., Nakajima, S., Minami, N., Umezawa, S., Kanamori, A., Takeda, H., Kawata, T., et al. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2417w · Cited by 39
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis
Sakurai, S., Jojima, T., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107703 · Cited by 39
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
Johnsson, K. M., JOHNSSON, E. K., Mansfield, T. A., Yavin, Y., Ptaszynska, A., & Parikh, S. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1153941 · Cited by 39
Self-citation
Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Zhou, B., Shi, Y., Fu, R., Ni, H., Gu, L., Si, Y.-X., Zhang, M., Jiang, K., Shen, J., Li, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.907340 · Cited by 41
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction
James, S. K., Erlinge, D., Storey, R. F., McGuire, D. K., de Belder, M., Björkgren, I., Johansson, P. A., Langkilde, A. M., Ridderstråle, W., Rizi, E. P., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.08.008 · Cited by 38
Self-citation

Authors: Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
Affiliations: Karolinska University Hospital (SE)
Uppsala University Hospital (SE)
Aintree University Hospital (GB)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)
Corresponding author: Bolinder, Jan
ORCID: Bolinder, Jan
Ljunggren, Östen
Kullberg, Joel
Wilding, John
Langkilde, Anna Maria
Sugg, Jennifer
Parikh, Shamik
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2012-03-01
Volume: 97
Issue: 3
Pages: 1020-1031
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2011-2260
OpenAlex: W2167245776
Cited by: 867
References: 36
Citations by year: 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
FWCI: 48.94
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
MeSH terms: Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks